1. ACS Med Chem Lett. 2012 Sep 17;3(10):850-5. doi: 10.1021/ml300225h.
eCollection  2012 Oct 11.

Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in 
Vivo.

Popovici-Muller J(1), Saunders JO(2), Salituro FG(3), Travins JM(1), Yan S(4), 
Zhao F(5), Gross S(1), Dang L(1), Yen KE(1), Yang H(1), Straley KS(1), Jin S(1), 
Kunii K(1), Fantin VR(6), Zhang S(7), Pan Q(7), Shi D(7), Biller SA(1), Su 
SM(1).

Author information:
(1)Agios Pharmaceuticals , 38 Sidney Street, Cambridge, Massachusetts 02139, 
United States.
(2)Ember Therapeutics , 855 Boylston Street, 11th Floor, Suite B, Boston, 
Massachusetts 02116, United States.
(3)Sage Therapeutics , 215 First Street, Cambridge, Massachusetts 02141, United 
States.
(4)Schrödinger, Inc. , 120 West 45th Street, New York, New York 10036, United 
States.
(5)Sundia MediTech Company, Ltd. , Building 8, 388 Jialilue Road, Zhangjiang 
High-Tech Park, Shanghai 201203, China.
(6)Oncology Research Unit, Pfizer Worldwide Research and Development , La Jolla 
Laboratories, San Diego, California 92121, United States.
(7)Shanghai ChemPartner Co., LTD , 998 Halei Road, Zhangjiang Hi-tech Park, 
Pudong New Area, Shanghai 201203, China.

Optimization of a series of R132H IDH1 inhibitors from a high throughput screen 
led to the first potent molecules that show robust tumor 2-HG inhibition in a 
xenograft model. Compound 35 shows good potency in the U87 R132H cell based 
assay and ∼90% tumor 2-HG inhibition in the corresponding mouse xenograft model 
following BID dosing. The magnitude and duration of tumor 2-HG inhibition 
correlates with free plasma concentration.

DOI: 10.1021/ml300225h
PMCID: PMC4025665
PMID: 24900389